Pharm

Eribulin

search

Eribulin, Halaven

  • Indications
  1. Metastatic Breast Cancer (refractory)
  2. Metastatic Liposarcoma (refractory, non-resectable)
  • Mechanism
  1. See Mitotic Inhibitor Chemotherapy
  2. Eribulin is a Halichondrin B analog with antineoplastic properties
    1. Dervied from the marine sponge Lissodendoryx.
  3. Eribulin is an anti-tubulin agent
    1. Binds to tubulin (at vinca doman)
    2. Inhibits tubulin polymerization and microtubule assembly
    3. Arrests Cell Cycle at G2/M phase
  • Medications
  1. Eribulin 1 mg/2ml intravenous solution
  • Dosing
  1. See other references for disease specific dosing protocols
  2. Adjust dosing in renal and hepatic Impairment
  3. Adults: 1.4 mg/m2 on days 1 and 8, in every 21 day cycles
  • Pharmacokinetics
  1. Hepatic excretion in feces unchanged
  • Safety
  1. Avoid in Lactation
  2. Avoid in pregnancy (all trimesters)
    1. Use reliable Contraception